Ask Question
15 February, 02:19

Mepolizumab and reslizumab improve asthma control by binding to

+3
Answers (2)
  1. 15 February, 02:31
    0
    Both Mepolizumab and reslizumab bind to interleukin-5 (IL-5), a key cytokine responsible for the differentiation, maturation, and activation of human eosinophils. Both antibodies bind to IL-5 and prevents binding to the interleukin 5 receptor alpha subunit, on the surface of eosinophil white blood cells. When these antibodies bind to IL-5, they stimulates B cell growth and increases immunoglobulin secretion, and this reduces the survival of eosinophils. Eosinophils, along with basophils and mast cells, are important mediators of allergic responses and severe asthmas.
  2. 15 February, 02:42
    0
    Interleukin-5 (IL-5). IL-5 is responsible for the recruitment and maturation of eosinophil. Eosinophils on the other hand are majorly involved in the inflammatory response in asthma - characterised by narrowing of the airways. Mepolizumab and reslizumab are, therefore, anti-IL-5
Know the Answer?
Not Sure About the Answer?
Get an answer to your question ✅ “Mepolizumab and reslizumab improve asthma control by binding to ...” in 📙 Biology if there is no answer or all answers are wrong, use a search bar and try to find the answer among similar questions.
Search for Other Answers